Premorbid GLP1-RA use, SGLT2i use associated with lower 60-day mortality compared to premorbid DPP4i use<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, June 30, 2021 (HealthDay News) — The use of certain classes of diabetes medications prior to severe COVID-19 infection is associated with lower mortality in patients with diabetes, according to a study published online June 16 in Diabetes Care<\/em>.<\/p>\n Anna R. Kahkoska, Ph.D., from the University of North Carolina at Chapel Hill, and colleagues compared premorbid glucagon-like peptide-1 receptor agonist (GLP1-RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) use versus premorbid dipeptidyl peptidase 4 inhibitor (DPP4i) use regarding severity of outcomes with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Analysis included 12,446 individuals identified through the National COVID Cohort Collaborative data set (January 2018 to February 2021) with a prescription for GLP1-RA, SGLT2i, or DPP4i within 24 months of positive SARS-CoV-2 polymerase chain reaction test.<\/p>\n The researchers found that 60-day mortality was 3.11 percent overall, but varied according to premorbid medication use (2.06 percent with GLP1-RA use, 2.32 percent with SGLT2i use, and 5.67 percent with DPP4i use). There was lower 60-day mortality with both GLP1-RA and SGLT2i use versus DPP4i use (odds ratios, 0.54 and 0.66, respectively). There were similar associations observed between use of both medications and total mortality, emergency room visits, and hospitalizations.<\/p>\n “Among SARS-CoV-2-positive adults, premorbid GLP1-RA and SGLT2i use, compared with DPP4i use, was associated with lower odds of mortality and other adverse outcomes, although DPP4i users were older and generally sicker,” the authors write.<\/p>\n Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n